The combination of amlodipine and angiotensin receptor blocker or diuretics in high-risk hypertensive patients: rationale, design and baseline characteristics
- PMID: 20445570
- PMCID: PMC3061000
- DOI: 10.1038/jhh.2010.45
The combination of amlodipine and angiotensin receptor blocker or diuretics in high-risk hypertensive patients: rationale, design and baseline characteristics
Abstract
The Chinese Hypertension Intervention Efficacy Study (CHIEF) is a multi-centre randomized controlled clinical trial comparing the effects of amlodipine+angiotensin II receptor blocker and amlodipine+diuretics on the incidence of cardiovascular events, represented as a composite of non-fatal stroke, non-fatal myocardial infarction and cardiovascular death events in high-risk Chinese hypertensive patients. The study also evaluates the long-term effects of lipid-lowering treatment and lifestyle modification. From October 2007 to October 2008, 13,542 patients were enrolled into the study in 180 centres in China. Patients will be followed up for 4 years. There was no difference in baseline characteristics between the two blood pressure arms.
Figures
References
-
- Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365 (9455:217–223. - PubMed
-
- Wang L.2002 National Nutrition and Health Survey: Report I [in Chinese]General Report.People's Medical Publishing House: Beijing; 2005
-
- Annals of Health of China Committee . 1999 Annals of Health of China [in Chinese] People's Health Press: Beijing, China; 2000.
-
- Asia Pacific Cohort Studies Collaboration Blood pressure and cardiovascular disease in the Asia Pacific Region. J Hypertens. 2003;21:707–716. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
